Evogene (EVGN) Stock Price, News & Analysis

Company Overview

Evogene Ltd. is a biotechnology company specializing in the use of computational and predictive biology technologies to design and develop novel products for agriculture and human health. Founded in 2002 and headquartered in Rehovot, Israel, the company has built a proprietary computational platform that integrates genomics, machine learning and data analytics to identify gene targets and biological traits. Evogene’s platform serves as the backbone for its research and development efforts, enabling the discovery of enhanced crop traits, microbial solutions and microbiome-based diagnostics and therapeutics.

In the agricultural sector, Evogene applies its platform to improve crop performance across a range of parameters, including yield enhancement, stress tolerance and resistance to pests and pathogens. The company’s ag biotech pipeline encompasses both gene products and microbial strains, with programs targeting major crops such as corn, wheat and soybean. Simultaneously, Evogene is expanding into the human health arena through its microbiome business units, which aim to develop diagnostic tools and therapeutic candidates that leverage beneficial microorganisms to address gastrointestinal and metabolic disorders.

Evogene collaborates with leading global partners in the agrochemical and life sciences industries, licensing its computationally discovered assets for further development and commercialization. These partnerships extend across North America, Europe and Asia, supporting field trials and clinical studies. The company maintains an extensive intellectual property portfolio covering its platform technologies and product candidates. Evogene trades on the NASDAQ under the ticker symbol EVGN and continues to advance its pipeline through a combination of in-house research, strategic alliances and third-party collaborations.

Key Stats

• Today's Range: $0.39 to $0.47
• 50-Day Range: $0.44 to $0.85
• 52-Week Range: $0.39 to $1.50
• Volume: 34.13 million shs
• Average Volume: 1.47 million shs
• Market Capitalization: $3.83 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Moderate Buy

Evogene Stock Analysis - MarketRank™

Evogene scored higher than 21% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Evogene has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 strong buy rating, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Evogene has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Evogene is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Evogene is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Evogene has a P/B Ratio of 0.32. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.53% of the float of Evogene has been sold short.

Short Interest Ratio / Days to Cover

Evogene has a short interest ratio ("days to cover") of 1.79, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Evogene has recently decreased by 20.29%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Evogene does not currently pay a dividend.

Dividend Growth

Evogene does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Evogene this week, compared to 2 articles on an average week.

Search Interest

3 people have searched for EVGN on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Evogene insiders have not sold or bought any company stock.

Percentage Held by Insiders

7.40% of the stock of Evogene is held by insiders.

Percentage Held by Institutions

10.40% of the stock of Evogene is held by institutions.

Company Calendar

• Last Earnings: 5/16/2026
• Today: 6/24/2026
• Next Earnings (Estimated): 8/26/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Chemicals
• Current Symbol: NASDAQ:EVGN
• CIK: 1574565
• Web: www.evogene.com
• Phone: (728) 931-1900
• Fax: 972-8946-6724
• Employees: 140
• Year Founded: 1999

Profitability

• EPS (Trailing Twelve Months): ($1.39)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$8.48 million
• Net Margins: -638.12%
• Pretax Margin: -949.08%
• Return on Equity: -158.82%
• Return on Assets: -80.37%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.79
• Quick Ratio: 2.76

Sales & Book Value

• Annual Sales: $3.85 million
• Price / Sales: 0.99
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.37 per share
• Price / Book: 0.32

Miscellaneous

• Outstanding Shares: 8,720,000
• Free Float: 8,073,000
• Market Cap: $3.83 million
• Optionable: No Data
• Beta: 1.35